Key Developments: Trius Therapeutics Inc (TSRX.W)
7.79USD
20 May 2013
$-0.20 (-2.50%)
$7.99
$8.05
$8.14
$7.79
1,100
3,079
$8.40
$4.44
Latest Key Developments (Source: Significant Developments)
Trius Therapeutics Inc Announces Exercise Of Underwriters' Option To Purchase Additional Shares For Common Stock Offering
Trius Therapeutics Inc announced that the underwriters of its previously announced public offering of common stock that priced on January 17, 2013, have exercised their option to purchase an additional 869,135 shares of common stock. With the sale of the additional shares, Trius will have sold a total of 7,169,135 shares of common stock in the public offering at a price to the public of $4.75 per share, resulting in expected aggregate gross proceeds to Trius of approximately $34.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trius. The offering, including the sale of the additional shares, is expected to close on or about January 24, 2013, subject to customary closing conditions. Trius anticipates using the net proceeds from the offering for general corporate purposes, including clinical trial, preclinical and other research and development expenses, capital expenditures, working capital and general and administrative expenses. Citigroup and Leerink Swann acted as joint book-running managers and Baird acted as a co-lead manager in the offering. Full Article
Trius Therapeutics Inc Announces Pricing Of Underwritten Public Offering
Trius Therapeutics Inc announced the pricing of an underwritten public offering of 6,300,000 shares of its common stock at a price to the public of $4.75 per share. The gross proceeds to Trius from this offering are expected to be approximately $29,925,000 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trius. The offering is expected to close on or about January 24, 2013. Citigroup and Leerink Swann are acting as joint book-running managers and Baird is acting as a co-lead manager in the offering. Trius has granted the underwriters a 30-day option to purchase up to an aggregate of 945,000 additional shares of common stock. Trius anticipates using the net proceeds from the offering for general corporate purposes, including clinical trial, preclinical and other research and development expenses, capital expenditures, working capital and general and administrative expenses. Full Article
Trius Therapeutics Inc Announces Issue Of Common Stock
Trius Therapeutics Inc announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Citigroup and Leerink Swann are acting as joint book-running managers and Baird is acting as a co-lead manager. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Full Article
Trius Therapeutics Inc Secures $25 Million Committed Equity Financing Facility With Terrapin Opportunity, L.P.
Trius Therapeutics Inc announced that it has obtained a committed equity financing facility under which it may from time to time sell up to $25 million of its registered common stock to Terrapin Opportunity, L.P., over a 24-month period. Trius is not obligated to utilize any of the $25 million facility and remains free to enter into and consummate other equity and debt financing transactions, subject to certain restrictions. Full Article
Trius Therapeutics Inc' Antibiotic Tedizolid Demonstrates High Efficacy In Patients With Cellulitis
Trius Therapeutics Inc announced results of a subgroup analysis from its first Phase 3 investigational study (TR701-112 Trial) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The data demonstrated that patients with severe cellulitis displayed higher clinical response rates following 6 days of treatment with a single 200 milligram daily dose of oral tedizolid phosphate than those treated for 10 days with two 600 milligram daily doses of oral linezolid. The pivotal Phase 3 trial examined efficacy and safety of tedizolid phosphate versus linezolid in 667 patients with ABSSSI recruited across sites in North America, South America and Europe. The cellulitis subgroup analysis of the 112 study compared the relative efficacies of tedizolid and linezolid in the European and U.S. patient populations with severe cellulitis with respect to the primary endpoints established by the European and U.S. (FDA) regulatory authorities. The results showed that European patients treated with tedizolid phosphate showed a higher clinical response rate (98% versus 91%) than those treated with linezolid with respect to the EMA primary endpoint. The European patients treated with tedizolid also showed a higher response rate than the linezolid treated patients (82% versus 76%) with respect to the FDA primary endpoint. The higher tedizolid efficacy in cellulitis was also seen in the U.S. patient population on the EMA endpoint (82% versus 78%) as well as the FDA endpoint (72% versus 69%). Full Article
Trius Therapeutics Inc Announces Issuance Of Tedizolid Patent In China
Trius Therapeutics Inc announced the issuance of Patent # 908206 by the State Intellectual Property Office of the People's Republic of China (PRC) that protects the composition of matter of the Company's Phase 3 investigational drug, tedizolid phosphate, through 2024. In addition to the issuance in China, patents for tedizolid phosphate have also issued in other jurisdictions including Australia, Canada, Europe, India, Japan, Mexico, Russia and the United States. Trius licensed the rights to tedizolid phosphate for Asia-Pacific and emerging markets to Bayer Pharmaceuticals and recently announced receiving a $5 million payment from Bayer after the completion of the "112" Phase 3 clinical study of tedizolid phosphate in acute bacterial skin and skin structure infections (ABSSSI). Trius retains the rights to tedizolid in the U.S., Canada and the EU countries. Full Article
Trius Therapeutics Inc Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares For Common Stock Offering
Trius Therapeutics Inc announced that the underwriters of its public offering that priced on January 26, 2012 have exercised in full their option to purchase an additional 1,290,000 shares of common stock. With the sale of the additional shares at a price to the public of $5.25 per share, the aggregate gross proceeds to Trius from this offering are expected to be approximately $51.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trius. The offering, including the sale of the additional shares, is expected to close on or about January 31, 2012, subject to customary closing conditions. Trius anticipates using the net proceeds from the offering for general corporate purposes, including clinical trial and other research and development expenses, capital expenditures, working capital and general and administrative expenses. Citigroup and Piper Jaffray & Co. are acting as joint book-running managers and Canaccord Genuity Inc. and Ladenburg Thalmann & Co. Inc. are acting as co-managers in the offering. Full Article
Trius Therapeutics, Inc. Prices Public Offering of Common Stock
Trius Therapeutics, Inc. announced the pricing of an underwritten public offering of 8,600,000 shares of its common stock at a price to the public of $5.25 per share. The gross proceeds to Trius from this offering are expected to be approximately $45.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trius. The offering is expected to close on or about January 31, 2012, subject to customary closing conditions. Citigroup and Piper Jaffray & Co. are acting as joint book-running managers and Canaccord Genuity Inc. and Ladenburg Thalmann & Co. Inc. are acting as co-managers in the offering. Trius has granted the underwriters a 30-day option to purchase up to an aggregate of 1,290,000 additional shares of common stock. Trius anticipates using the net proceeds from the offering for general corporate purposes, including clinical trial and other research and development expenses, capital expenditures, working capital and general and administrative expenses. Full Article
Trius Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock
Trius Therapeutics, Inc. announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Citigroup and Piper Jaffray & Co. are acting as joint book-running managers. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Full Article
Trius Therapeutics, Inc. Reports Positive Results From First Phase 3 Trial Of Tedizolid In Acute Bacterial Skin And Skin Structure Infections
Trius Therapeutics, Inc. announced that tedizolid phosphate met the primary objective of non-inferiority for the efficacy outcome of early clinical response versus the comparator linezolid (Zyvox) in patients with acute bacterial skin and skin structure infections (ABSSSI). Tedizolid also met all secondary efficacy outcomes in this first of two pivotal Phase 3 trials that were designed to support the filing of a New Drug Application (NDA) with the FDA as well as a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA). The pivotal Phase 3 trial, designated TR701-112, examined the efficacy and safety of a once daily 200 milligram dose of oral tedizolid phosphate over a 6-day course of therapy (followed by four days of placebo) versus a twice daily 600 milligram dose of oral linezolid over a 10-day course of therapy in 667 patients recruited across sites in North America, South America and Europe. In the Intent to Treat (ITT) analysis set, tedizolid achieved the primary objective of non-inferiority (10% non-inferiority margin) to linezolid in the primary and secondary efficacy endpoints. Both tedizolid and linezolid were generally well tolerated with comparable overall safety profiles, with drug-related treatment emergent adverse events (TEAE) reported in 24.2% of tedizolid patients versus 31% of linezolid treated patients. Full Article
BRIEF-Trius Therapeutics up in premarket after tedizolid study results
NEW YORK, March 25 - Trius Therapeutics Inc : * Up 6.6 percent to $7.45 in premarket after tedizolid study results
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
